Japan Cancels Rest Of H1N1 Flu Vaccine Ordered From GSK
This article was originally published in PharmAsia News
Executive Summary
Japan negotiated cancellation of part of its order of H1N1 flu vaccine from U.K.-based GlaxoSmithKline because the nation still has vaccine left over from the pandemic
|
Japan negotiated cancellation of part of its order of H1N1 flu vaccine from U.K.-based GlaxoSmithKline because the nation still has vaccine left over from the pandemic. The canceled order is for about 24 million doses, about a third of the original order from GSK. According to the Ministry of Health, Labor and Welfare, the agreement does not include a cancellation fee. Still unsettled is a similar cancellation being negotiated by the ministry with Swiss-based Novartis for 49 million vaccine doses. (Click here for more - a subscription may be required) "Japan Cancels Part Of Flu Vaccine Deal With GlaxoSmithKline" - Nikkei (Japan) (3/26/10) |